[
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  }
]